JP2021518111A5 - - Google Patents

Info

Publication number
JP2021518111A5
JP2021518111A5 JP2020549002A JP2020549002A JP2021518111A5 JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5 JP 2020549002 A JP2020549002 A JP 2020549002A JP 2020549002 A JP2020549002 A JP 2020549002A JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5
Authority
JP
Japan
Prior art keywords
cells
nucleic acid
cell
amino acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020549002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518111A (ja
JP7314161B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021833 external-priority patent/WO2019178085A1/en
Publication of JP2021518111A publication Critical patent/JP2021518111A/ja
Publication of JP2021518111A5 publication Critical patent/JP2021518111A5/ja
Priority to JP2023114641A priority Critical patent/JP7696958B2/ja
Application granted granted Critical
Publication of JP7314161B2 publication Critical patent/JP7314161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020549002A 2018-03-14 2019-03-12 ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法 Active JP7314161B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023114641A JP7696958B2 (ja) 2018-03-14 2023-07-12 ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643139P 2018-03-14 2018-03-14
US62/643,139 2018-03-14
PCT/US2019/021833 WO2019178085A1 (en) 2018-03-14 2019-03-12 Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023114641A Division JP7696958B2 (ja) 2018-03-14 2023-07-12 ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法

Publications (3)

Publication Number Publication Date
JP2021518111A JP2021518111A (ja) 2021-08-02
JP2021518111A5 true JP2021518111A5 (cg-RX-API-DMAC7.html) 2022-03-18
JP7314161B2 JP7314161B2 (ja) 2023-07-25

Family

ID=67907266

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020549002A Active JP7314161B2 (ja) 2018-03-14 2019-03-12 ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法
JP2023114641A Active JP7696958B2 (ja) 2018-03-14 2023-07-12 ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023114641A Active JP7696958B2 (ja) 2018-03-14 2023-07-12 ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法

Country Status (13)

Country Link
US (2) US12606603B2 (cg-RX-API-DMAC7.html)
EP (2) EP3765487A4 (cg-RX-API-DMAC7.html)
JP (2) JP7314161B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260021083A (cg-RX-API-DMAC7.html)
CN (1) CN112088165A (cg-RX-API-DMAC7.html)
AU (2) AU2019234580B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018534A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093791A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091984A1 (cg-RX-API-DMAC7.html)
IL (1) IL277268A (cg-RX-API-DMAC7.html)
MX (2) MX2020009464A (cg-RX-API-DMAC7.html)
SG (1) SG11202008926RA (cg-RX-API-DMAC7.html)
WO (1) WO2019178085A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7438123B2 (ja) 2018-03-14 2024-02-26 シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体
US20260151429A1 (en) * 2022-08-25 2026-06-04 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090257994A1 (en) * 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
KR101763499B1 (ko) 2012-11-07 2017-07-31 화이자 인코포레이티드 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체
EP2929045B1 (en) 2012-12-05 2020-12-02 SOLA Biosciences LLC Protein expression enhancing polypeptides
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
ES2738705T3 (es) 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
HK1256130A1 (zh) 2015-07-21 2019-09-13 City Of Hope 用於嵌合抗原受体和其他受体的表达的t细胞
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
JP7189019B2 (ja) * 2016-02-05 2022-12-13 シティ・オブ・ホープ 中枢神経系の癌の治療のための操作されたt細胞の投与
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
JP7295795B2 (ja) 2016-07-29 2023-06-21 ジュノー セラピューティクス インコーポレイテッド 免疫調節ポリペプチドならびに関連する組成物および方法
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US12083148B2 (en) 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
JP7438123B2 (ja) 2018-03-14 2024-02-26 シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体

Similar Documents

Publication Publication Date Title
JP2021518108A5 (cg-RX-API-DMAC7.html)
US20250043013A1 (en) Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
JP6543626B2 (ja) 多部分シグナル伝達タンパク質およびその使用
EP3445847B1 (en) Immunomodulatory il2r fusion proteins and uses thereof
US20170292118A1 (en) Method for modulating car-induced immune cells activity
JP7696958B2 (ja) ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法
EP4382119A1 (en) A kit for use in the treatment of hematological cancer
JP2025540251A (ja) 血液癌の治療において使用するためのキット
WO2023102109A1 (en) Ex vivo cytokine priming strategies for preparing activated cd26-high immune cells and uses in cancer therapies
JP2023529443A (ja) 抗cd171キメラ抗原受容体
KR20260032682A (ko) 두경부암 치료를 위한 egfr을 표적으로 하는 키메라항원 수용체 및 이를 발현하는 t 세포 치료제